Abstract:Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit their benefits. Metabolic reprogramming appears to be one of the crucial barriers to immunotherapy. The deprivation of required nutrients and altered metabolites not only promote tumor progression but also confer dysfunction on immune cells in the tumor microenvironment (TME). Glycolysis plays a central role in metabolic reprogramming and immunoregulation in the TME, and many therapies targeting glycolysis have been developed, and their combinations with ICIs are in preclinical and clinical trials. Additional attention has been paid to the role of amino acids, lipids, nucleotides and mitochondrial biogenesis in metabolic reprogramming and clinical anti-tumor therapy. This review attempts to describe reprogramming metabolisms within tumor cells and immune cells, from the aspects of glycolysis, amino acid metabolism, lipid metabolism, nucleotide metabolism and mitochondrial biogenesis and their impact on immunity in the TME, as well as the significance of targeting metabolism in anti-tumor therapy, especially in combination with ICIs. In particular, we highlight the expression mechanism of programmed cell death (ligand) 1 [PD-(L)1] in tumor cells and immune cells under reprogramming metabolism, and discuss in detail the potential of targeting key metabolic pathways to break resistance and improve the efficacy of ICIs based on results from current preclinical and clinical trials. Besides, we draw out biomarkers of potential predictive value in ICIs treatment from a metabolic perspective.

Hurdle or Thruster: Glucose Metabolism of T Cells in Anti-Tumour Immunity

Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function

Glucose Metabolism Regulates T Cell Activation, Differentiation, and Functions

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Shielding the double‐edged sword: negative regulation of the innate immune system

Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression

Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer

Targeting metabolism of breast cancer and its implications in T cell immunotherapy

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity

Metabolic interventions: A new insight into the cancer immunotherapy

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment

Unlocking the potential of T‐cell metabolism reprogramming: Advancing single‐cell approaches for precision immunotherapy in tumour immunity

Different Glucose Metabolic Features According to Cancer and Immune Cells in the Tumor Microenvironment

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment